Agile Therapeutics Inc (NASDAQ:AGRX) Expected to Post Earnings of -$0.08 Per Share

Wall Street analysts expect that Agile Therapeutics Inc (NASDAQ:AGRX) will announce earnings per share (EPS) of ($0.08) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.09). Agile Therapeutics posted earnings per share of ($0.11) during the same quarter last year, which indicates a positive year-over-year growth rate of 27.3%. The company is scheduled to report its next quarterly earnings results on Thursday, November 7th.

On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.39) to ($0.34). For the next financial year, analysts anticipate that the business will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.77) to $0.11. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03.

Several equities research analysts have commented on the company. Zacks Investment Research downgraded Agile Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.45.

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Agile Therapeutics by 2,219.3% in the second quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock worth $108,000 after purchasing an additional 73,238 shares during the last quarter. BlackRock Inc. raised its stake in shares of Agile Therapeutics by 27.2% in the second quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock worth $247,000 after purchasing an additional 36,212 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Agile Therapeutics by 33.3% in the first quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after purchasing an additional 104,222 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Agile Therapeutics by 129.8% in the second quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock worth $2,530,000 after purchasing an additional 978,672 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 5.6% in the second quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock worth $3,291,000 after purchasing an additional 120,403 shares during the last quarter. 43.73% of the stock is currently owned by institutional investors and hedge funds.

Agile Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $1.13. The company had a trading volume of 11,263 shares, compared to its average volume of 1,233,939. The stock’s 50 day moving average price is $1.18 and its two-hundred day moving average price is $1.31. Agile Therapeutics has a 12 month low of $0.51 and a 12 month high of $1.70. The company has a market capitalization of $51.50 million, a PE ratio of -1.93 and a beta of 0.38.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Story: Cash Flow

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.